HPAPI contract manufacturing to value $14.6 billion by 2030
European Pharmaceutical Review
OCTOBER 18, 2022
However, during the second half, the surge in demand for vaccines to fight the coronavirus enhanced the industry’s need for raw materials and product intermediates of API molecules. However, due to the small volumes required for dosage, small-scale providers are also gaining importance, findings from the report show.
Let's personalize your content